Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of IRL201104 in Healthy Volunteers
NCT05921591Phase 1Completed
- Sponsor
- Revolo Biotherapeutics
- Start
- May 2023
- Primary completion
- Sep 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IRL201104 in eosinophilic esophagitis (EoE) (3 arms), sponsored by Revolo Biotherapeutics. Primary endpoint: Treatment Emergent Adverse Events at 28 days. Started May 2023; status: completed.
02
Drugs
IRL201104
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT05921591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05921591.